Anavex swings to FY26 Q3 net income of $7.82 million
AVXL•Cash position and runway
Cash and cash equivalents rose to $118.3 million at June 30, 2026; funding runway expected into mid to late fiscal 2028.
Alzheimer’s program update
For Alzheimer’s, the company submitted all clinical trial data to a newly opened IND and plans FDA talks on Phase 3 design for ANAVEX2-73-AD-005.
Fiscal third-quarter results
Anavex posted fiscal Q3 net income of $7.8 million, or $0.08 a share, versus a $13.2 million loss.
Operating income was $6.7 million, swinging from a $14.5 million operating loss, on stock-based compensation reversals tied to employee terminations.
Rett and Fragile X development plans
For Rett, Anavex filed an FDA meeting request to add pediatric patients to Phase 3 ANAVEX2-73-RS-005. A Fragile X IND submission is targeted for September.
